Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study.
暂无分享,去创建一个
E. Van Cutsem | H. Lenz | A. Cercek | T. Bekaii-Saab | S. Siena | Christina Wu | P. Kasi | K. Ciombor | T. André | K. Ng | J. Strickler | C. Cremolini | D. Bajor | A. Kardosh | J. Hubbard | A. Coveler | M. Stecher | C. Fountzilas | W. Feng | A. Paulson | E. Élez | F. Sanchez